pretickt

Tempus AI TEM stock

Tempus AI, Inc. · Healthcare · end-of-day data as of Nov 13, 2026

Tempus AI
TEM · $12.7B
$71.60-5.7%
Nov 13, 2026 · close
$50$60$70$80SepOctNov9:3016:003 months +45.1%Nov 13close
▲ Bullish readings 5
  • Price target at$78.63 +9.8%
  • ConsensusBuy · 21
  • Trendbullish
  • MA20×50Golden 3d ago
  • Sector▲ +15.9%
Neutral
  • Earnings in102d
  • RSI47
  • Support-2.1%
  • Resistance+1.9%
  • Off 52w high-19.6%
  • Volume0.8x
  • Bollingerlower half
  • News0.00
  • 52w range$41–$89
  • ATR+9.5%
  • Off ATH-31.4%
  • MAs2 of 4
▼ Bearish readings 3
  • FCF yield-1.2%
  • Insiders-$89.37M
  • MACD-0.01

Updates with the 15-min delayed price; analysts, insiders and news are from the last close. Not a forecast or investment advice.

The average 12-month analyst price target for Tempus AI TEM is $78.63, 9.8% above the last close of $71.60 on Nov 13, 2026; targets range from $50.00 to $100.00. Rating consensus: Buy.

What changed

Tempus AI TEM · Nov 13, 2026

Tempus AI fell 5.7% on Nov 13 while healthcare stocks rose

The drop left the week to Nov 13 down 5.9%, despite an 11.0% jump on Nov 9.

  • Last close (Nov 13): TEM -5.7% = market (SPY) -0.4% + Healthcare sector +0.8% + TEM on its own -6.1%.
  • Last 5 sessions to Nov 13: TEM -5.9% = market (SPY) +2.6% + Healthcare sector -1.7% + TEM on its own -6.8%.
  • Tempus AI rose 11.0% on Nov 9, 2026, about 3.9 times its usual daily move.

Wording by an AI model from pretickt's data; the dated facts under it are the platform's own. Not investment advice.

Analyst price targets and predictions

16 firms with a target in the last 12 months · last close $71.60 · as of Nov 13, 2026

— actual price● bullish target● bearish target┄ last close, high, average and low targethover a dot to see the analysts behind it ·wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets
⇔⇕$100HIGH$78.63AVERAGE$71.60TODAY$50.00LOWNov 25Apr 26Sep 26Feb 27Jul 27Dec 27+26%-17%+36%+1%-8%-30%+15%-4%+28%
21

Strong buy 2Buy 8Hold 10Sell 1Strong sell 0

21 analysts in November 2026: 10 rate it a buy or strong buy (48%), 10 a hold and 1 a sell or strong sell. A year earlier, 53% rated it a buy or strong buy.

Is Tempus AI a good stock to buy?

Tempus AI is strong on 2 of the 5 questions about the business; weak on economics. With a loss over the last 12 months, Tempus AI has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage some edge
  3. Economics losing money
  4. Execution mixed
  5. Fragility sturdy
  6. Price below its peers
TEM: the 6 questions, card by card

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.

Snapshot

  • P/E—
  • P/E vs sector—
  • P/E vs own—
  • Price target at+9.8%
  • ConsensusBuy
  • Market cap$12.7B
  • FCF yield-1.2%
  • Insiders-$89.37M
  • Earnings in102d
  • News0.00

Why it moved

Tempus AI TEM fell 5.7% on Nov 13, 2026.

The market (SPY) fell 0.4%; Healthcare stocks rose 0.4%. Most of the move is specific to Tempus AI TEM.

Market (SPY)-0.4%
Healthcare sector+0.8%
TEM specific-6.1%

0 stories on the day (30-day average 1.2).

Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.

Price and events

⇔⇕$44.38$57.00$69.63$82.25Nov 25Feb 26May 26Aug 26Nov 26EEEAEA

Last close $71.60 · +5.4% over 1y · E earnings · D dividend · S split · A analyst rating change

Technicals

Tempus AI TEM closed at $71.60 on Nov 13, 2026, 24.6% above its 200-day moving average of $57.45 and 1.7% below its 50-day moving average of $72.84. It is 19.6% below its 52-week high of $89.09; its 52-week low is $40.77.

  • Trendbullish
  • Sector▲ +15.9%
  • MAs20▼ 50▼ 100▲ 200▲
  • Above MAs2 of 4 above
  • MA20×50Golden 3d ago
  • RSI47
  • Support-2.1%
  • Resistance+1.9%
  • Off 52w high-19.6%
  • Off ATH-31.4%
  • 52w range$71.60
  • Bollingerlower half
  • MACD-0.01
  • ATR+9.5%
  • Volume0.8x

Revenue and free cash flow

Q3 FY2026: Revenue +23.1% year over year, free cash flow -1.3% of revenue, operating margin -13.8%.

RevenueFree cash flow
Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Q3 FY2026Sep 30, 2026$412M-0.08-$5.54M64.8%-13.8%-3.6%
Q2 FY2026Jun 30, 2026$382M0.03-$18.62M64.4%-19.8%1.5%
Q1 FY2026Mar 31, 2026$348M-0.71-$83.34M63.8%-24.3%-36.2%
Q4 FY2025Dec 31, 2025$367M-0.30-$43.12M64.7%-16.7%-14.8%
Q3 FY2025Sep 30, 2025$334M-0.46-$128M62.8%-18.3%-23.9%
Q2 FY2025Jun 30, 2025$315M-0.25$34.65M62.0%-19.6%-13.6%
Q1 FY2025Mar 31, 2025$256M-0.40-$109M60.7%-26.9%-26.6%
Q4 FY2024Dec 31, 2024$201M-0.08-$47.21M60.8%-25.3%-6.5%

Peers

20D
1SOLVSolventum$89.08+0.3%-5.4%-3.9%99.0$15.14B
2BAXBaxter$25.81+0.3%-14.0%-13.8%—$13.35B
3TEMTempus AI$71.60-5.7%-19.6%+9.8%—$12.7B
4COOCooper Companies$62.65+0.7%-30.3%+3.9%21.4$11.91B
5ALGNAlign Technology$168.32+0.8%-16.0%+15.4%24.5$11.86B
6TECHBio-Techne$72.80+0.1%-0.1%-7.7%66.2$11.44B
7DVADaVita$174.56+0.3%-29.5%+41.9%13.7$10.98B
8PODDInsulet$152.48+2.1%-57.0%+19.5%24.8$10.58B

Data as of Nov 13, 2026 close.

Latest news

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.